Are Investors Putting Too Much Faith In Novo Nordisk?

Novo Nordisk carries a steep multiple, but also an uncommonly strong franchise in biopharmaceuticals

May 1, 2014 at 6:30PM

It is hard to be too critical of Novo Nordisk (NYSE:NVO), as this Danish biopharma specialist practically mints money with its leading franchises in diabetes, hemophilia, and growth hormones. The company is facing more challenges than it has in the past, though, as biosimiliars and new formulations threaten to change the insulin market and reimbursement pressures become more visible. It is hard to call Novo Nordisk underpriced, but a stock that looks poised to generating market-matching returns behind the security of good economic moats does have some appeal on a risk-adjusted basis.

An unusual disappointment
Novo Nordisk rarely misses estimates, but it looks like business was a little weaker this quarter than analysts expected. Revenue rose 2% as reported (and 7% in local currencies), missing the average sell-side guess by 3%. Most of that was due to underestimated currency impacts, but there was an underlying 1% operational miss in the diabetes business.

Diabetes revenue rose 1% as reported and 6% in local currencies, with noticeable weakness in Europe due in part to reimbursement pressures. Modern insulin sales were very mixed, with Levemir up 21% against a 3% decline in NovoRapid and a 2% decline in NovoMix, the latter two of which can likely be tied back to their exclusion from Express Scripts' formulary. Victoza sales were up 9%, while "Other" declined 22% on generic competition to Prandin.

Biopharma sales were fine, rising 5% in Danish kroner and 10% in local currencies as NovoSeven sales growth of 11% outweighed a 2% decline in Norditropin.

Novo Nordsk also earned back some lost revenue through better than expected margins. Gross margin improved 1.1 percentage points on better mix (beating expectations by 0.4 percentage points), and operating income rose 6% to beat expectations by about 2%.

And an equally unusual guide down
Management's guidance for the year is going to lead sell-side revenue targets down probably around 2%, and that's not something that happens very often here. Foreign exchange is having a bigger negative impact on Novo than expected, but the company's management also made some concerning comments regarding a slowing GLP-1 market.

As Novo's share as seemed fairly steady against AstraZeneca's Bydureon/Byetta and Victoza sales growth does seem to be slowing, I can understand the concern. With Lilly moving closer toward to US approval of its GLP-1 drug dulaglutide, a drug which showed top line non-inferiority to Victoza in the AWARD-6 study, Novo could be looking at more pressure here in the relatively near future.

A mostly positive pipeline update
Novo's news on its pipeline was generally pretty positive. The DEVOTE outcomes study for Tresiba is enrolling faster than expected and management believes it will be able to conduct an interim analysis in mid-2015, possibly accelerating approval by a year.

Novo also announced that it intends to begin a Phase IIa proof of concept study for an oral insulin (NN1953) in the first half of 2015. As a reminder, Novo will also be reporting phase 2 data on an oral form of semaglutide (GLP-1) in 2015.

On a less positive note, Ryzodeg missed the mark on a non-inferiority study comparing it to NovoRapid. Novo Nordisk also announced that despite strong Phase III data, it won't be filing its long-acting Factor VIII drug N8-GP until 2017/2018 due to supply constraints. Data suggests that this will be a viable competitor to Biogen Idec's Eloctate, but by the time Novo reaches the market Baxter will likely have its long-acting FVIII drug on the market as well.

Last and not least, Novo has an under-followed and generally unnoticed de novo effort under way in inflammatory disease, with three compounds in Phase II testing for rheumatoid arthritis and Crohn's disease. These drugs would only add about $1 per share in value at this point, but it could be the beginning of something that turns into a meaningful business down the line.

Times are changing in diabetes, or are they?
There is a lot of talk of change and challenges in the diabetes market. To be sure, reimbursement pressure is a very real issue, as seen by Novo Nordisk losing its place in Express Scripts' formulary to AstraZeneca and Lilly. There is also the rising threat of biosimilar substitution, though Sanofi did file suit against Lilly for its attempt to market a biosimilar Lantus and more than one company has abandoned biosimilar insulin as too challenging.

The bottom line
Novo Nordisk could have some upside from oral GLP-1 (a drug that could be a multibillion-dollar drug like Januvia) and oral insulin. I think the company won't have the most explosive potential return in the drug space, but there are some opportunities when you consider the company's strong market share (near 50% in insulin), focused pipeline, and demonstrated history of strong returns on capital.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That’s beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor’s portfolio. To see our free report on these stocks, just click here now.

Stephen D. Simpson, CFA has no position in any stocks mentioned. The Motley Fool recommends Express Scripts. The Motley Fool owns shares of Express Scripts. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers